Cancer Australia

A National Data Strategy to improve access to information about breast and ovarian cancer. 18 page document.

Report from a plenary symposium held at the 34th Annual Scientific Meeting of the Clinical Oncological Society of Australia. 17 page document.

The aim of this review was to compare third generation aromatase inhibitors (AIs) to antioestrogens and progestins in the treatment of post-menopausal women with hormone receptor-positive metastatic breast cancer.

This review was designed to update the report A Systematic Review of Intraoperative Radiotherapy in Early Stage Breast Cancer published in 2002 by ASERNIP-S (Australian Safety and Efficacy Register of New Interventional Procedures - Surgical). 3 page document.

This is a summary that may be helpful for general practitioners in answering patient’s questions about trastuzumab. It is based on clinical practice guideline  HERG - Recommendations for Trastuzumab (Herceptin®) for treatment of HER2-positive breast cancer (291.85 kB).

A systematic review of the best available evidence on the use of trastuzumab (Herceptin®) in breast cancer.

The workshop recommendations provide guidance to multidisciplinary teams and health services about medicolegal implications of a multidisciplinary approach to cancer care. 19 page document.

The primary research questions of this systematic review assessed the benefits and harms of using sentinel node biopsy compared to axillary lymph node dissection to detect cancer spread in early (operable) breast cancer and cancer recurrence and survival outcomes for patients receiving sentinel node biopsy. 49 page document.

The aim of this systematic review was to determine the effectiveness of taxane-containing chemotherapy regimens, compared to non-taxane-containing chemotherapy regimens. 35 page document.

These guidelines provide guidance for clinicians about the use of Herceptin® in the treatment of both early and advanced disease.

This document is an update of Chapter 6 and Appendix G contained in the NBCC**
Breast imaging: a guide for practice, 2002 (resource code BIG).

** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

2 page document.

The research question addressed by the systematic review was: Does the use of magnetic resonance imaging (MRI) instead of, or in addition to, other modalities improve the diagnosis of breast cancer during screening of asymptomatic women at high risk of breast cancer? Where possible, the review also investigated the impact of age and risk factor subgroup upon the relative diagnostic performance of MRI. 79 page document.

Training workshop for Aboriginal and Torres Strait Islander health workers. 20 page document.

Ovarian cancer in Australia: an overview, 2006 brings together under one cover the most recent information available on the epidemiology, public health and health services impact of ovarian cancer on Australia women. 47 page document.

Breast cancer in Australia: an overview, 2006 brings together under one cover the most recent information available on the epidemiology, public health and health services impact of breast cancer in Australia. 96 page document.

Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer.

This document supplements guideline recommendation 19 about the use of tamoxifen for the management of post-menopausal women with hormone receptor-positive early breast cancer contained in the National Breast Cancer Centre** 'Clinical Practice Guidelines for the Management of Early Breast Cancer', 2nd edition, 2001 (page 9).

** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Supporting evidence for the national breast cancer centre hormonal therapies guidelines working group. 45 page document.

A report and recommendations from a National Breast Cancer Forum series - July 2006

This 2006 report is a preliminary review of the evidence available regarding the use of intraoperative radiotherapy for the treatment of early breast cancer, identifying any significant new evidence and developments since 2002.

This guide indicates steps to be taken in investigating symptoms that could be breast cancer. The individual patient history and circumstances etc.

Addendum to  SSW-1 - Evidence Relevant to Guidelines for the Investigation of Breast Symptoms (1.04 MB)

Key findings document (4pages) of BHS-1 National Breast Cancer Centre** Breast Health Survey Technical Report (995.2 kB).

** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

The information in this guide is intended to assist general practioners assess if a woman with persistent, unexplained symptoms may have ovarian cancer. The guide is based on the Clinical practice guidelines for the management of women with epithelial ovarian cancer.

Executive summary of  BNC-1 Specialist breast nurse competency standards and associated educational requirments (377.75 kB)

16 page document.

This project was initiated by the National Breast Cancer Centre (NBCC)** with the aim of defining a set of SBN Competency Standards considered integral to optimising outcomes for women with breast cancer. 66 page document.

See also   BNC-2 Executive summary of Specialist breast nurse competency standards and educational requirements (96.76 kB)

** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

A guide for Health Service Providers.

This Breast Health Survey was conducted by the National Breast Cancer Centre** in late 2003 to explore the knowledge, attitudes and behaviour of women across Australia in relation to the early detection of breast cancer. 182 page document.

See also the key findings -  BHS-2 Key findings of NBCC** Breast Health Survey Technical Report (38.75 kB)

** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Please also refer to the addendum  SSW-2 Addendum to Strengthening Support for Women with Breast Cancer (19.57 kB 2005-09-01)

A discussion paper on the 2004 scoping study of current International and Australian cancer service accreditation systems and processes. 235 page document.

For health professionals. 1 page document.

A follow-up study to the National Multidisciplinary Care Demonstration Project (resource code MDC). 62 page document.

A four page brochure summary.

Intended to assist all clinicians involved in the investigation of women with breast symptoms or image-detected breast lesions, primarily pathologists, surgeons and radiologists.

A summary guide for psychosocial care of adults with cancer for health professionals (resource PCA). This summary provides an overview of the key emotional issues to consider when treating patients with cancer.

85 page document.

62 page document.

The aim of this report is to present an overview of published research about the psychosocial impact of breast cancer on women’s body image and sexuality. It also considers the supportive care issues for women and their partners, as illustrated through a series of focus group interviews. 67 page document.

The guidelines are formulated with the aim of closing the gap on information for clinicians (both specialists and general practitioners) and other health professionals, so that awareness of ovarian cancer is raised and the possibility of earlier diagnosis and optimal treatment is realised. 213 page document.

77 page document.

This report is the second to describe in full the epidemiology of ductal carcinoma in situ (DCIS) in New South Wales (NSW). It analyses data from the NSW Central Cancer Registry (CCR) in 1995-2000. 53 page document.

See also  DCW-2 Summary of Ductal Carcinoma in Situ (DCIS) in women in New South Wales 1995-2000 (151.01 kB)

This summary presents information about women diagnosed with ductal carcinoma in situ (DCIS) in New South Wales (NSW) in 1995-2000. It describes aspects of the epidemiology and pathology of the disease, as well as its surgical management. 6 page document.

See also  DCW-1 Ductal Carcinoma in Situ (DCIS) in women in New South Wales 1995-2000 (798.06 kB)

This position statement applies to screening methods for the early detection of breast cancer in asymptomatic women (women without breast changes).

A 61 page summary report of MDC - Multidisciplinary Care (MDC) in Australia: a National Demonstration Project in Breast Cancer.

Summary of the systemic review Use of taxanes for adjuvant and neo-adjuvant treatment of early and locally advanced breast cancer.

Systematic review use of taxanes for adjuvant and neo-adjuvant treatment of early and locally advanced breast cancer. (47 pages)

A summary of the review is also available.

A seven page summary of the review Use of luteinising hormone-releasing hormone agonists for adjuvant treatment of early breast cancer.

A systematic review to summarise current evidence about the role of LHRH agonists in the adjuvant treatment of ER+ early breast cancer in pre-menopausal women, with a view to providing evidence to support the information needs of women with breast cancer, clinicians, media and policy makers. (56 pages)

A seven page summary of the review is also available.

The Clinical practice guidelines for the management and support of younger women with breast cancer have been developed to complement existing guidelines and focus on issues that are specific to the age and/or life stage of younger women, and aim to assist younger women and their doctors in making decisions about all aspects of breast cancer care.